# Goserelin

Canonical source: https://retacompare.com/encyclopedia/goserelin

GnRH super-agonist delivered as a biodegradable subcutaneous depot.

Reference facts

Also known asZoladexCategoryGnRH & ReproductiveMechanism of actionGnRH super-agonist delivered as a biodegradable subcutaneous depot.TargetsGnRH receptorIndications under research or approvedProstate cancer, Breast cancer (premenopausal, ER+), EndometriosisRegulatory status (reference entry)FDA-approved (1989)Half-life~4 hours (subcutaneous depot)Sequence notesDecapeptide pyroGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-AzaGly-NH2.Molecular weight (Da)1269Originator / sponsorAstraZenecaFirst reported1976
    Primary References

Zoladex FDA label


    Explore research articles about Goserelin


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Zoladex FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019726s057_020578s033lbl.pdf